|Nanoviricides, Inc. |
|Stock Report Launch |
May 05, 2008
OTC Symbol: NNVC
|Summary: The Company is a development stage company that is creating special purpose nanomaterials for viral therapy.|
|Price at Research Launch:||$0.69|| |
|Prepared by: Ludlow Capital Research|
REGISTER FOR UPDATES
Request an Investor Packet on NNVC
NanoViricieds (NNVC) utilize creative and unique nanomaterials for targeting and destroying viruses. The company's nanoviricide(TM) drug candidates are designed to specifically attack enveloped virus particles and to dismantle them, as opposed to vaccines which work to prevent the delivery of the virus payload. This unique approach makes NNVC a interesting play in the field of viral therapy.
NanoViricides is using this unique viral approach for use and potential destruction of such viral diseases including H5N1 bird flu, seasonal influenza, HIV, hepatitis C, rabies, dengue fever, and Ebola virus, among others.
Due to the company's recent test results with such diseases as Ebola and HIV, and their different approach to viral therapy, Ludlow BioVentures is initiating research coverage on the company with a B+ rating, and a 9-month price target of $3.00 per share.
For updates on this research opinion, or additional information on the company register online here.
About Ludlow BioVentures, Inc
Based in New York City, Ludlow BioVenture is a venture capital and research advisory firm with a specific focus on the biotechnology sector. The goal of the firm is to promote investments into biotech ventures worldwide. Ludlow BioVentures owns and operates the Ludlow BioVenture Index, which tracks a wide basket of US traded large and small cap biotechnology stocks. www.ludlowcapital.com/bioventures/
|Legend: E-Estimated. NA-Not Available. NM-Not Meaningful. NR-Not Ranked. UR-Under Review.|
|Office: 135 Wood Street, # 205 |
West Haven, CT 06516
|Chairman: Dr. Anil R. Diwan Ph.D. |
CFO: Dr. Eugene Seymour MD, MPH
|Founded: UR |
Analyst: Thomas Latino, PhD